FDA Extends Enforcement Deadline for Drug Supply Chain Security Act (DSCSA) Requirements
| by: Sumeet Singh, Founder & Chairman | Article Posted: September 6, 2023 |
The U.S. Food and Drug Administration (FDA) recently announced an extension on the enforcement of specific provisions under the Drug Supply Chain Security Act (DSCSA). The enforcement date, which was initially set for November 27, 2023, has now been pushed to November 27, 2024.
The Goal of This Delay
This decision aims to grant additional time to trading partners and stakeholders, which encompasses drug and device manufacturers, wholesale distributors, dispensers, repackagers, to adapt and ensure efficient implementation of “electronic tracing at the package level, to achieve robust supply chain security under the DSCSA while helping ensure continued patient access to prescription drugs.”
This move underscores the FDA’s understanding and recognition of the technical and operational challenges that trading partners might face in achieving a seamless and interoperable system by the initial 2023 deadline.
Comment From FDA
“While FDA generally expects trading partners to have the systems and processes in place to meet these requirements as of November 27, 2023, we recognize that some technical and operational issues, including issues involving trading partners and other affected stakeholders, may not be fully resolved by that time. The Agency also understands that additional time beyond November 27, 2023 may be needed for systems to stabilize and be fully interoperable for accurate, secure, and timely electronic data exchange. This guidance is intended to provide clarity and flexibility to trading partners to help ensure continued patient access to prescription drugs as the supply chain transitions to the interoperable, electronic product tracing at the package level under the DSCSA. The compliance policies in this guidance can help trading partners throughout the supply chain implement the requirements under section 582(g)(1) of the FD&C Act by accommodating the additional time that may be needed to implement, troubleshoot, and mature their systems and processes while supporting the continued availability of products to patients.”
Effects on Supply Chain
This one-year delay aims to provide an ample window for the pharmaceutical supply chain to stabilize its intricate systems and processes, ensuring smooth transactions across the board. The FDA is dedicated to supporting a cohesive and collaborative effort among all stakeholders in the pursuit of the DSCSA’s overarching objectives of enhancing traceability and security in the prescription drug supply chain.
Insight from Sumeet Singh, Founder & Chairman
“The FDA’s recent delay in implementing the DSCSA highlights just how big of a challenge that changes in regulations can be for the drug supply chain”, said Sumeet Singh, CEO. “It shows that it’s not just about using new technology, but also about how we manage and support that technology. As the DSCSA steers us into an era where States will be restructuring their regulatory frameworks, the demands on supply chain entities to synchronize and strengthen their systems will further intensify. In the heart of this transformation, the convergence of technology and managed services emerges as the linchpin to navigate the evolving regulatory landscape.”
It’s evident that with this decision, the FDA continues its commitment not just to security and traceability but also to ensuring that patient care remains at the forefront of its actions.
The official guidance from the FDA can be read here: https://www.fda.gov/media/171592/download.
Subscribe to our newsletter:
Disclaimer: Pharma Solutions makes every effort to provide accurate information in the content it offers. However, the information provided is “as is” and Pharma Solutions makes no warranties, express or implied, as to the content provided. Pharma Solutions assumes no liability or responsibility for any errors or omissions in the content provided. Laws and regulations that are referenced herein may change over time and as such the content offered is not to be interpreted as advice. Pharma Solutions shall not be liable for any damages whatsoever incurred in connection with the use or performance of this information.